hotspot -WSS

hotspot

author：comprehensive 2025-09-27 07:51:49 - browse：573

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Trial using CRISPR to edit HIV out of cells disappoints

WSS

U.K. decision on ALS drug has neurologists, advocates up in arms

Scientists uncover potential path to treating deadly childhood tumor

Testing GLP

Bird flu in dairy cattle: New measures to control spread to humans

6 surprising facts about sugar

Cancer, immunology, HIV research ensnared in fetal tissue politics

explore

hotspot

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Gut bacteria may contribute to kidney autoimmunity, study finds

Moonlake's readout produced a cash windfall. Risks remain

Young boy dies in trial for Pfizer Duchenne gene therapy

Medical leaders decry Supreme Court decision on affirmative action

Study: Black kids more likely to die after surgery than white kids

Jerome Adams on the need for new antivirals for Covid

Bring on the sabbaticals for nurses

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Scientific mystery highlights the blind spots in genomics databases

leisure time

Bird flu reported in person exposed to presumably infected cattle

Adam's Take: Intra

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Oral obesity drug from Viking Therapeutics hits key early target

Medicare Advantage 2025 payments will dip, Biden administration says

Insurer loopholes limit power of law against surprise medical bills

focus

Wikipedia

entertainment

hotspot